Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer

  • Authors:
    • Ines Gockel
    • Markus Moehler
    • Kirsten Frerichs
    • Daniel Drescher
    • Tran Tong Trinh
    • Friedrich Duenschede
    • Thomas Borschitz
    • Katrin Schimanski
    • Stefan Biesterfeld
    • Kerstin Herzer
    • Peter R. Galle
    • Hauke Lang
    • Theodor Junginger
    • Carl C. Schimanski
  • View Affiliations

  • Published online on: October 1, 2008     https://doi.org/10.3892/or_00000081
  • Pages: 845-850
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

This study aimed to define the co-expression pattern of target receptor tyrosine kinases (RTKs) in human esophageal adenocarcinoma and squamous cell cancer. The co-expression pattern of vascular endothelial growth factor receptor (VEGFR)1-3, platelet-derived growth factor receptor (PDGFR)α/β and epidermal growth factor receptor 1 (EGFR1) was analyzed by RT-PCR in 50 human esophageal cancers (35 adenocarcinomas and 15 squamous cell cancers). In addition, IHC staining was applied for the confirmation of the expression and analysis of RTK localisation. The adenocarcinoma samples revealed VEGFR1 (97%), VEGFR2 (94%), VEGFR3 (77%), PDGFRα (91%), PDGFRβ (85%) and EGFR1 (97%) expression at different intensities. Ninety-four percent of the esophageal adenocarcinomas expressed at least four out of six RTKs. Similarly, squamous cell cancers revealed VEGFR1 (100%), VEGFR2 (100%), VEGFR3 (53%), PDGFRα (100%), PDGFRβ (87%) and EGFR1 (100%) expression at different intensities. All esophageal squamous cell carcinomas expressed at least four out of six RTKs. While VEGFR1-3 and PDGFRα and EGFR1 was expressed by tumor cells, PDGFRβ was restricted to stromal cells, which also depicted a PDGFRα expression. Our results revealed a high rate of RTK co-expression in esophageal adenocarcinoma and squamous cell cancer and may encourage application of multi-target RTK inhibitors within a multimodal concept as a promising novel approach for innovative treatment strategies.

Related Articles

Journal Cover

October 2008
Volume 20 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Gockel I, Moehler M, Frerichs K, Drescher D, Trinh TT, Duenschede F, Borschitz T, Schimanski K, Biesterfeld S, Herzer K, Herzer K, et al: Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer. Oncol Rep 20: 845-850, 2008.
APA
Gockel, I., Moehler, M., Frerichs, K., Drescher, D., Trinh, T.T., Duenschede, F. ... Schimanski, C.C. (2008). Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer. Oncology Reports, 20, 845-850. https://doi.org/10.3892/or_00000081
MLA
Gockel, I., Moehler, M., Frerichs, K., Drescher, D., Trinh, T. T., Duenschede, F., Borschitz, T., Schimanski, K., Biesterfeld, S., Herzer, K., Galle, P. R., Lang, H., Junginger, T., Schimanski, C. C."Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer". Oncology Reports 20.4 (2008): 845-850.
Chicago
Gockel, I., Moehler, M., Frerichs, K., Drescher, D., Trinh, T. T., Duenschede, F., Borschitz, T., Schimanski, K., Biesterfeld, S., Herzer, K., Galle, P. R., Lang, H., Junginger, T., Schimanski, C. C."Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer". Oncology Reports 20, no. 4 (2008): 845-850. https://doi.org/10.3892/or_00000081